67.17
price down icon3.92%   -2.74
after-market After Hours: 64.99 -2.18 -3.25%
loading
Corcept Therapeutics Inc stock is traded at $67.17, with a volume of 1.61M. It is down -3.92% in the last 24 hours and down -8.49% over the past month. Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$69.91
Open:
$68.95
24h Volume:
1.61M
Relative Volume:
1.24
Market Cap:
$7.12B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
53.31
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-0.62%
1M Performance:
-8.49%
6M Performance:
+0.37%
1Y Performance:
+73.70%
1-Day Range:
Value
$66.94
$70.74
1-Week Range:
Value
$66.94
$70.74
52-Week Range:
Value
$32.33
$117.33

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
Name
Corcept Therapeutics Inc
Name
Phone
650.688.8803
Name
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
Employee
500
Name
Twitter
Name
Next Earnings Date
2025-02-17
Name
Latest SEC Filings
Name
CORT's Discussions on Twitter

Compare CORT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CORT
Corcept Therapeutics Inc
67.17 7.41B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-06-23 Upgrade Truist Hold → Buy
Apr-11-23 Initiated SVB Securities Market Perform
Apr-04-23 Initiated Piper Sandler Overweight
Feb-15-23 Downgrade Jefferies Buy → Hold
Aug-01-22 Downgrade Truist Buy → Hold
Jul-27-22 Upgrade Jefferies Hold → Buy
Jun-27-22 Resumed Canaccord Genuity Buy
Feb-02-22 Initiated Canaccord Genuity Buy
Jan-28-22 Initiated Truist Buy
Aug-05-20 Downgrade Jefferies Buy → Hold
Sep-24-19 Initiated Jefferies Buy
Sep-06-19 Initiated H.C. Wainwright Buy
Feb-04-19 Downgrade B. Riley FBR Buy → Neutral
Aug-10-18 Reiterated Stifel Hold
May-31-18 Downgrade Stifel Buy → Hold
Mar-09-18 Initiated B. Riley FBR, Inc. Buy
Aug-31-17 Initiated Stifel Buy
Feb-02-17 Initiated Ladenburg Thalmann Buy
Apr-21-15 Initiated FBR Capital Outperform
Jan-13-14 Downgrade Stifel Buy → Hold
Aug-09-13 Downgrade Janney Buy → Neutral
Aug-09-13 Downgrade Ladenburg Thalmann Buy → Neutral
Feb-21-12 Reiterated JMP Securities Mkt Outperform
Jan-06-10 Upgrade Ladenburg Thalmann Neutral → Buy
Jul-17-08 Initiated Rodman & Renshaw Mkt Outperform
Jun-21-07 Upgrade Punk, Ziegel & Co Mkt Perform → Accumulate
View All

Corcept Therapeutics Inc Stock (CORT) Latest News

pulisher
Jul 31, 2025

Earnings call transcript: Corcept Therapeutics Q2 2025 earnings beat expectations By Investing.com - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

Corcept (NASDAQ:CORT) Misses Q2 Sales Targets - TradingView

Jul 31, 2025
pulisher
Jul 31, 2025

Corcept: Q2 Earnings Snapshot - San Francisco Chronicle

Jul 31, 2025
pulisher
Jul 31, 2025

Corcept Therapeutics falls as revenue guidance disappoints investors By Investing.com - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

CORCEPT THERAPEUTICS INC SEC 10-Q Report - TradingView

Jul 31, 2025
pulisher
Jul 31, 2025

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

Insiders Favor These 3 High Growth Companies - Yahoo.co

Jul 31, 2025
pulisher
Jul 29, 2025

Corcept Therapeutics' Q2 Earnings: A Critical Inflection Point for Growth and Innovation - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

What To Expect From Corcept’s (CORT) Q2 Earnings - Yahoo.co

Jul 29, 2025
pulisher
Jul 29, 2025

Technical Charts Suggest Momentum Shift in Corcept Therapeutics IncorporatedSmart Allocation Stock Pick Insights Gaining Interest - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Published on: 2025-07-28 23:53:14 - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionPortfolio Diversification Stock Ideas From Experts - beatles.ru

Jul 28, 2025
pulisher
Jul 28, 2025

When is Corcept Therapeutics Incorporated stock expected to show significant growthCapitalize on momentum-driven investment opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Why Corcept Therapeutics Incorporated stock attracts strong analyst attention Daily Equity Signal Strength Summary Report - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about Corcept Therapeutics IncorporatedInvest confidently with professional market insights - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) - Yahoo Finance

Jul 28, 2025
pulisher
Jul 27, 2025

Why is Corcept Therapeutics Incorporated stock attracting strong analyst attentionFree Investment Community - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk - Yahoo Finance

Jul 27, 2025
pulisher
Jul 25, 2025

10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey

Jul 25, 2025
pulisher
Jul 25, 2025

Corcept Therapeutics’ ALS Study: A Potential Game-Changer? - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Should I buy Corcept Therapeutics Incorporated stock before earningsHigh-octane financial growth - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Corcept Therapeutics Incorporated a good long term investmentConsistent high-performance stocks - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Corcept Therapeutics Incorporated stock priceUnbelievable profit margins - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Corcept Therapeutics Incorporated stockExceptional financial outcomes - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Is Corcept Therapeutics Incorporated stock overhyped or has real potentialFree Market Dynamics Reports - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant - Yahoo.co

Jul 24, 2025
pulisher
Jul 24, 2025

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire

Jul 24, 2025
pulisher
Jul 23, 2025

Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance

Jul 23, 2025
pulisher
Jul 22, 2025

Corcept Therapeutics Incorporated Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga

Jul 21, 2025
pulisher
Jul 20, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st

Jul 20, 2025
pulisher
Jul 18, 2025

agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - Yahoo Finance

Jul 18, 2025

Corcept Therapeutics Inc Stock (CORT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):